Abbisko Therapeutics Achieves Milestone with NMPA Acceptance for Pimicotinib Targeting TGCT Treatment Abbisko Therapeutics proudly announces the NMPA's acceptance of their NDA for Pimicotinib, an innovative drug aimed at treating TGCT, showcasing promising clinical efficacy.

Abbisko Therapeutics Achieves Milestone with NMPA Acceptance for Pimicotinib Targeting TGCT Treatment #China #Shanghai #Abbisko #Pimicotinib #TGCT

Abbisko's Pimicotinib Shows Promise in Treating Chronic Graft-versus-Host Disease at ASH 2024 Abbisko Therapeutics revealed promising results from its Phase 2 study of pimicotinib for chronic Graft-versus-Host Disease at ASH 2024. The data suggests significant clinical efficacy.

Abbisko's Pimicotinib Shows Promise in Treating Chronic Graft-versus-Host Disease at ASH 2024 #China #Shanghai #Abbisko #Pimicotinib #cGvHD